{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:29:39Z","timestamp":1777577379249,"version":"3.51.4"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI114292"],"award-info":[{"award-number":["AI114292"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0232355","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T18:02:59Z","timestamp":1588183379000},"page":"e0232355","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination"],"prefix":"10.1371","volume":"15","author":[{"given":"Elizabeth M.","family":"Parzych","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutoyo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole A.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-141X","authenticated-orcid":true,"given":"James M.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"issue":"24","key":"pone.0232355.ref001","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Rts SCTP","year":"2012","journal-title":"N Engl J Med"},{"issue":"9988","key":"pone.0232355.ref002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"Rts SCTP","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"pone.0232355.ref003","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"MT White","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0232355.ref004","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.vaccine.2009.10.022","article-title":"Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys","volume":"28","author":"S Pichyangkul","year":"2009","journal-title":"Vaccine"},{"issue":"7","key":"pone.0232355.ref005","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.4049\/jimmunol.1003783","article-title":"Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference","volume":"187","author":"EK Forbes","year":"2011","journal-title":"J Immunol"},{"issue":"6","key":"pone.0232355.ref006","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"SJ McConkey","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"pone.0232355.ref007","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4049\/jimmunol.155.1.236","article-title":"Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria","volume":"155","author":"TM Daly","year":"1995","journal-title":"J Immunol"},{"issue":"7","key":"pone.0232355.ref008","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.159.7.3400","article-title":"Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells","volume":"159","author":"C Hirunpetcharat","year":"1997","journal-title":"J Immunol"},{"issue":"1","key":"pone.0232355.ref009","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.172.1.379","article-title":"A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies","volume":"172","author":"MJ Blackman","year":"1990","journal-title":"J Exp Med"},{"issue":"8","key":"pone.0232355.ref010","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.4049\/jimmunol.142.8.2835","article-title":"A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii","volume":"142","author":"JM Burns","year":"1989","journal-title":"J Immunol"},{"issue":"2","key":"pone.0232355.ref011","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0166-6851(93)90141-J","article-title":"Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1","volume":"60","author":"JA Chappel","year":"1993","journal-title":"Mol Biochem Parasitol"},{"issue":"3","key":"pone.0232355.ref012","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF03401557","article-title":"Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys","volume":"1","author":"S Kumar","year":"1995","journal-title":"Mol Med"},{"issue":"12","key":"pone.0232355.ref013","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1084\/jem.193.12.1403","article-title":"Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria","volume":"193","author":"RA O'Donnell","year":"2001","journal-title":"J Exp Med"},{"issue":"3","key":"pone.0232355.ref014","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/infdis\/173.3.765","article-title":"Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1","volume":"173","author":"AF Egan","year":"1996","journal-title":"J Infect Dis"},{"issue":"15","key":"pone.0232355.ref015","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.vaccine.2005.11.028","article-title":"Phase I safety and immunogenicity trial of FMP1\/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine","volume":"24","author":"CF Ockenhouse","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"pone.0232355.ref016","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.vaccine.2005.11.037","article-title":"Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya","volume":"25","author":"JA Stoute","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"pone.0232355.ref017","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1371\/journal.pctr.0010034","article-title":"Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial","volume":"1","author":"MA Thera","year":"2006","journal-title":"PLoS clinical trials"},{"issue":"7","key":"pone.0232355.ref018","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1371\/journal.pctr.0010032","article-title":"Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children","volume":"1","author":"MR Withers","year":"2006","journal-title":"PLoS clinical trials"},{"issue":"1","key":"pone.0232355.ref019","doi-asserted-by":"crossref","first-page":"e8787","DOI":"10.1371\/journal.pone.0008787","article-title":"Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1\/Alhydrogel with and without CPG 7909 in malaria naive adults","volume":"5","author":"RD Ellis","year":"2010","journal-title":"PLoS One"},{"key":"pone.0232355.ref020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1475-2875-12-29","article-title":"Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01","volume":"12","author":"N Otsyula","year":"2013","journal-title":"Malaria journal"},{"issue":"3","key":"pone.0232355.ref021","doi-asserted-by":"crossref","first-page":"e4708","DOI":"10.1371\/journal.pone.0004708","article-title":"Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya","volume":"4","author":"BR Ogutu","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"pone.0232355.ref022","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/IAI.01467-06","article-title":"Enhanced protection against malaria by a chimeric merozoite surface protein vaccine","volume":"75","author":"Q Shi","year":"2007","journal-title":"Infect Immun"},{"issue":"42","key":"pone.0232355.ref023","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1016\/j.vaccine.2010.08.018","article-title":"Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection","volume":"28","author":"JR Alaro","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"pone.0232355.ref024","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1128\/IAI.00211-12","article-title":"Evaluation of the Immunogenicity and Vaccine Potential of Recombinant Plasmodium falciparum Merozoite Surface Protein 8","volume":"80","author":"JR Alaro","year":"2012","journal-title":"Infect Immun"},{"issue":"10","key":"pone.0232355.ref025","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1128\/IAI.00522-13","article-title":"A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies","volume":"81","author":"JR Alaro","year":"2013","journal-title":"Infection and immunity"},{"issue":"1","key":"pone.0232355.ref026","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-45440-4","article-title":"Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody","volume":"9","author":"JS Eacret","year":"2019","journal-title":"Scientific reports"},{"issue":"6168","key":"pone.0232355.ref027","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/333074a0","article-title":"A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains","volume":"333","author":"DC Kaslow","year":"1988","journal-title":"Nature"},{"issue":"3\u20134","key":"pone.0232355.ref028","first-page":"193","article-title":"Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study","volume":"8","author":"B Sharma","year":"2008","journal-title":"In Silico Biol"},{"issue":"10","key":"pone.0232355.ref029","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1128\/IAI.68.10.5530-5538.2000","article-title":"A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies","volume":"68","author":"AW Stowers","year":"2000","journal-title":"Infect Immun"},{"issue":"4","key":"pone.0232355.ref030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-3024.1989.tb00679.x","article-title":"Identification of a peptide sequence of the 25 kD surface protein of Plasmodium falciparum recognized by transmission-blocking monoclonal antibodies: implications for synthetic vaccine development","volume":"11","author":"A van Amerongen","year":"1989","journal-title":"Parasite Immunol"},{"issue":"5","key":"pone.0232355.ref031","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.174.5.1203","article-title":"Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals","volume":"174","author":"PJ Barr","year":"1991","journal-title":"J Exp Med"},{"issue":"Suppl 3","key":"pone.0232355.ref032","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1590\/S0074-02761992000700028","article-title":"Induction of Plasmodium falciparum transmission-blocking antibodies by recombinant Pfs25","volume":"87","author":"DC Kaslow","year":"1992","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"6","key":"pone.0232355.ref033","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1086\/515331","article-title":"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"177","author":"CF Ockenhouse","year":"1998","journal-title":"The Journal of infectious diseases"},{"key":"pone.0232355.ref034","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000058850","article-title":"Transmission-blocking vaccines","volume":"80","author":"DC Kaslow","year":"2002","journal-title":"Chemical immunology"},{"issue":"7","key":"pone.0232355.ref035","doi-asserted-by":"crossref","first-page":"e2636","DOI":"10.1371\/journal.pone.0002636","article-title":"Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51","volume":"3","author":"Y Wu","year":"2008","journal-title":"PLoS One"},{"issue":"10","key":"pone.0232355.ref036","doi-asserted-by":"crossref","first-page":"e0163144","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and Immunogenicity of Pfs25-EPA\/Alhydrogel(R), a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naive Adults","volume":"11","author":"KR Talaat","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"pone.0232355.ref037","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00486-17","article-title":"Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant Pfs25, a Leading Transmission-Blocking Vaccine Candidate","volume":"86","author":"EM Parzych","year":"2018","journal-title":"Infect Immun"},{"issue":"2","key":"pone.0232355.ref038","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine Adjuvants: from 1920 to 2015 and Beyond","volume":"3","author":"A Di Pasquale","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"pone.0232355.ref039","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s40064-015-0972-0","article-title":"The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm","volume":"4","author":"TR Ghimire","year":"2015","journal-title":"Springerplus"},{"issue":"9","key":"pone.0232355.ref040","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/eji.201243124","article-title":"MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant","volume":"43","author":"MT Orr","year":"2013","journal-title":"Eur J Immunol"},{"issue":"12","key":"pone.0232355.ref041","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1128\/IAI.01056-13","article-title":"Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay","volume":"81","author":"K Miura","year":"2013","journal-title":"Infection and immunity"},{"issue":"35","key":"pone.0232355.ref042","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/j.vaccine.2016.06.066","article-title":"Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay","volume":"34","author":"K Miura","year":"2016","journal-title":"Vaccine"},{"issue":"12","key":"pone.0232355.ref043","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1128\/IAI.62.12.5576-5580.1994","article-title":"Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum","volume":"62","author":"DC Kaslow","year":"1994","journal-title":"Infect Immun"},{"issue":"1","key":"pone.0232355.ref044","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12936-016-1464-6","article-title":"Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates","volume":"15","author":"SM Lee","year":"2016","journal-title":"Malaria journal"},{"issue":"2","key":"pone.0232355.ref045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.molbiopara.2006.03.011","article-title":"Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes","volume":"148","author":"C Mehlin","year":"2006","journal-title":"Molecular and biochemical parasitology"},{"issue":"52","key":"pone.0232355.ref046","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1016\/j.vaccine.2015.09.093","article-title":"Recent advances in recombinant protein-based malaria vaccines","volume":"33","author":"SJ Draper","year":"2015","journal-title":"Vaccine"},{"issue":"15","key":"pone.0232355.ref047","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/S0264-410X(02)00701-6","article-title":"Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials","volume":"21","author":"L Zou","year":"2003","journal-title":"Vaccine"},{"issue":"28","key":"pone.0232355.ref048","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.vaccine.2013.04.034","article-title":"Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle","volume":"31","author":"RL Shimp","year":"2013","journal-title":"Vaccine"},{"issue":"43","key":"pone.0232355.ref049","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1016\/j.vaccine.2010.08.022","article-title":"Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen","volume":"28","author":"G Mlambo","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"pone.0232355.ref050","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/IAI.01438-13","article-title":"Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding","volume":"82","author":"R Kumar","year":"2014","journal-title":"Infect Immun"},{"issue":"8","key":"pone.0232355.ref051","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1128\/IAI.65.8.3024-3031.1997","article-title":"Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds","volume":"65","author":"A Egan","year":"1997","journal-title":"Infect Immun"},{"issue":"3","key":"pone.0232355.ref052","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/eji.200324514","article-title":"Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response","volume":"34","author":"M Hensmann","year":"2004","journal-title":"Eur J Immunol"},{"issue":"9598","key":"pone.0232355.ref053","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(07)61542-6","article-title":"Safety of the RTS,S\/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I\/IIb trial","volume":"370","author":"JJ Aponte","year":"2007","journal-title":"Lancet"},{"issue":"24","key":"pone.0232355.ref054","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1056\/NEJMoa0807773","article-title":"Safety and immunogenicity of RTS,S\/AS02D malaria vaccine in infants","volume":"359","author":"S Abdulla","year":"2008","journal-title":"N Engl J Med"},{"key":"pone.0232355.ref055","doi-asserted-by":"crossref","first-page":"40312","DOI":"10.1038\/srep40312","article-title":"Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate","volume":"7","author":"AJ Radtke","year":"2017","journal-title":"Scientific reports"},{"issue":"5","key":"pone.0232355.ref056","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1128\/IAI.02980-14","article-title":"Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes","volume":"83","author":"KP Patra","year":"2015","journal-title":"Infection and immunity"},{"issue":"1","key":"pone.0232355.ref057","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/IAI.72.1.253-259.2004","article-title":"Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations","volume":"72","author":"C Coban","year":"2004","journal-title":"Infection and immunity"},{"issue":"4","key":"pone.0232355.ref058","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1371\/journal.pctr.0020012","article-title":"Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria","volume":"2","author":"E Malkin","year":"2007","journal-title":"PLoS Clin Trials"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0232355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T13:13:52Z","timestamp":1696079632000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0232355"}},"subtitle":[],"editor":[{"given":"Andrew M.","family":"Blagborough","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,4,29]]},"references-count":58,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0232355","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,29]]}}}